Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

Inclusion Criteria: * Males and Females \>18 years of age. Females of child bearing potential will undergo urine pregnancy testing and be required to use appropriate methods of birth control. * ICG and fluorescein angiographic characteristics consistent with active, leaking PCV with subfoveal lesions and/or subfoveal hemorrhage, lipid exudates, PED or fluid diagnosed within the past 6 months or diagnosed as newly active within the past 6 months. Subjects who completed the 24 month follow up in the original FVF3671s protocol may enter the study without necessarily demonstrating active exudative PCV at enrollment. * Best-Corrected ETDRS Visual Acuity at 4 meters between 20/20 - 20/800. * Lesion size - no limitations. * Lesions Characteristics - leaking lesions consistent with PCV. No limitations on hemorrhage, fibrosis or atrophy. * No therapy (includes non foveal laser, PDT, intravitreal steroids, TTT, radiotherapy, or anti-VEGF therapy) or intraocular surgery within the past 30 days for any condition. * Clear ocular media to allow for photography/angiography. * Ability to provide written informed consent and comply with study assessments for the full duration of the study. Exclusion Criteria: * Patients with features of age related macular degeneration such as abundant drusen and demographic features consistent with this diagnosis. * Allergy to Fluorescein, ICG, Iodine, Shellfish. * Pregnancy (positive pregnancy test) * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated. * Participation in another simultaneous medical investigation or trial. * Exclude other anti-VEGF agents as therapy options. * History of previous subfoveal laser. * Advanced glaucoma (IOP \> 25 or cup/disc ration \> 0.8) * Any condition in the opinion of the investigator that would interfere with disease status/progression or jeopardize patients' participation in the study.